stockrow
Friday 6 November 2026
Export PDEX’s income statement to Excel — free account
Pro-Dex, Inc.
PDEX Healthcare Medical Instruments & Supplies
Pro-Dex, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $77.5 million, up 16.5% from fiscal 2025.
- Revenue
- +11.0%
- EPS
- −33.6%
- Free cash flow
- +177.8%
- Total debt
- +42.2%
Quarter to September 2026, against a year earlier
62.91
1.71
+2.79%
Follow PDEX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
18.40 | 13.84 | 13.28 | 11.09 |
+8 more quarters Free account |
P/S ratio |
2.78 | 2.44 | 2.11 | 1.73 | |
P/FCF ratio |
20.76 | 28.08 | 22.67 | 20.88 | |
P/Operating CF |
34.09 | (691.88) | 96.28 | 35.00 | |
P/B ratio |
4.48 | 3.97 | 3.48 | 3.00 | |
Price to Tangible BV |
5.25 | 4.67 | 4.14 | 3.00 | |
EV/Sales |
2.77 | 2.49 | 2.15 | 1.72 | |
EV/EBITDA |
14.80 | 13.39 | 13.26 | 9.86 | |
EV/Operating CF |
19.30 | 26.62 | 21.87 | 19.22 | |
EV/FCF |
20.69 | 28.67 | 23.15 | 20.74 | |
Quick Ratio |
2.45 | 2.40 | 2.10 | 2.21 | |
Current Ratio |
4.19 | 4.10 | 3.67 | 4.03 | |
Net Debt/EBITDA |
(0.18) | 1.00 | 0.96 | (0.23) | |
Debt/Assets |
16.02% | 17.80% | 19.08% | 12.86% | |
Debt/Equity |
0.25 | 0.28 | 0.32 | 0.19 | |
Asset Turnover |
1.13 | 1.14 | 1.07 | 1.18 | |
Operating CF/Net income |
2.13 | (0.10) | 0.41 | 1.63 | |
Capex/Depreciation |
(0.85) | (0.50) | (0.31) | (0.22) | |
Interest Coverage |
13.52 | 13.07 | 15.39 | 23.11 | |
Research and Development Expense of Revenue |
5.89% | 4.98% | 4.15% | 3.93% | |
Selling, General and Administrative Expense of Revenue |
10.37% | 12.48% | 11.09% | 9.38% | |
Intangible Assets out of Total Assets |
0.09 | 0.10 | 0.10 | 0.00 | |
Share Based Compensation of Revenue |
0.66% | 0.87% | 0.93% | 0.88% | |
Graham Net Nets |
0.12 | 0.14 | 0.15 | 0.23 | |
Graham Number |
36.04 | 37.49 | 34.29 | 31.63 | |
Earnings Yield |
5.43% | 7.22% | 7.53% | 9.02% | |
Free Cash Flow Yield |
4.82% | 3.56% | 4.41% | 4.79% | |
Revenue per Share |
6.41 | 6.33 | 6.23 | 5.74 | |
Operating CF per Share |
2.02 | (0.08) | 0.51 | 1.10 | |
Capex per Share |
(0.11) | (0.06) | (0.03) | (0.02) | |
Free Cash Flow per Share |
1.92 | (0.15) | 0.48 | 1.08 | |
Cash per Share |
4.05 | 2.90 | 3.43 | 2.71 | |
Shareholders Equity per Share |
15.39 | 14.77 | 14.12 | 12.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.39 | 14.77 | 14.12 | 12.81 | |
Free Cash Flow |
6.14 | (0.48) | 1.52 | 3.50 | |
Working Capital |
41.06 | 40.27 | 39.07 | 36.99 | |
Capital Expenditures |
(0.35) | (0.20) | (0.11) | (0.07) | |
Net Current Asset Value |
26.70 | 26.37 | 23.93 | 28.56 | |
EV/EBIT |
16.46 | 14.84 | 14.86 | 10.94 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
16.51 | 14.54 | 14.55 | 11.01 | |
| Other line items | |||||
Average Receivables |
18.46 | 19.66 | 17.82 | 18.31 | |
Average Payables |
4.64 | 4.44 | 5.60 | 4.90 | |
Average Inventory |
21.73 | 21.84 | 22.89 | 20.66 | |
Average Assets |
70.44 | 67.85 | 69.63 | 61.32 | |
Average Common Equity |
45.43 | 42.13 | 40.24 | 36.73 |
Columns are period end dates · fundamentals updated 5 Nov 2026